Maybe my estimates are backwards? I just thought that BP would be able to launch a new product more successfully than Syneos Health if we go alone....regardless of the higher price. A lot of variables come into play. Regardless I think our revenue will be at least $500M for either scenario, with more upside both in 2020 and future years if going alone. I still prefer them to license combo and possibly even mono at the right price and keep everything else.